[
    [
        {
            "time": "2021-Q1",
            "original_text": "血制品批签发数据跟踪报告：批签发同比下降 主要品种供给明显下滑",
            "features": {
                "keywords": [
                    "血制品",
                    "批签发",
                    "同比下降",
                    "供给下滑"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物制品"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "血制品批签发数据跟踪报告：批签发同比下降 主要品种供给明显下滑",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-Q1",
            "original_text": "医药行业2020年年报及2021年一季报总结：Q1业绩复苏回暖 看好CXO、疫苗、创新器械和服务等高景气板块",
            "features": {
                "keywords": [
                    "医药行业",
                    "年报",
                    "一季报",
                    "业绩复苏",
                    "CXO",
                    "疫苗",
                    "创新器械",
                    "服务",
                    "高景气板块"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CXO",
                    "疫苗",
                    "医疗器械",
                    "医疗服务"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业2020年年报及2021年一季报总结：Q1业绩复苏回暖 看好CXO、疫苗、创新器械和服务等高景气板块",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021",
            "original_text": "5000亿医药巨无霸现身！国药集团家底好惊人",
            "features": {
                "keywords": [
                    "医药",
                    "国药集团",
                    "巨无霸"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "5000亿医药巨无霸现身！国药集团家底好惊人",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-Q1",
            "original_text": "天坛生物(600161)：Q1业绩略超预期 规模化优势有望进一步扩大",
            "features": {
                "keywords": [
                    "天坛生物",
                    "Q1业绩",
                    "略超预期",
                    "规模化优势",
                    "扩大"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物制品"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天坛生物(600161)：Q1业绩略超预期 规模化优势有望进一步扩大",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-Q1",
            "original_text": "天坛生物(600161)2020年年报及2021年一季报点评：2021Q1业绩恢复略超预期 国内血制品龙头再扬帆",
            "features": {
                "keywords": [
                    "天坛生物",
                    "年报",
                    "一季报",
                    "Q1业绩",
                    "恢复",
                    "略超预期",
                    "血制品",
                    "龙头"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物制品"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天坛生物(600161)2020年年报及2021年一季报点评：2021Q1业绩恢复略超预期 国内血制品龙头再扬帆",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]